Galectin Therapeutics Files 8-K

Ticker: GALT · Form: 8-K · Filed: Mar 5, 2025 · CIK: 1133416

Galectin Therapeutics INC 8-K Filing Summary
FieldDetail
CompanyGalectin Therapeutics INC (GALT)
Form Type8-K
Filed DateMar 5, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: disclosure, sec-filing

TL;DR

GALECTIN THERAPEUTICS INC filed an 8-K on March 5, 2025. Standard disclosure.

AI Summary

Galectin Therapeutics Inc. filed an 8-K on March 5, 2025, reporting on its current activities. The filing primarily serves as a notification of information and exhibits, without detailing specific financial transactions or material events that would typically impact stock price.

Why It Matters

This 8-K filing indicates Galectin Therapeutics Inc. is providing updates or disclosures to the SEC, which could contain important information for investors.

Risk Assessment

Risk Level: low — The filing is a routine 8-K, likely containing standard disclosures or exhibits, rather than announcing a significant event.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Galectin Therapeutics Inc.?

The filing is a Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, indicating it's for reporting purposes as of March 5, 2025.

When was this 8-K report filed?

The report was filed on March 5, 2025.

In which state is Galectin Therapeutics Inc. incorporated?

Galectin Therapeutics Inc. is incorporated in Nevada.

What is the principal executive office address for Galectin Therapeutics Inc.?

The principal executive office is located at 4960 PEACHTREE INDUSTRIAL BOULEVARD, STE 240, NORCROSS, GA 30071.

What is the telephone number for Galectin Therapeutics Inc.?

The registrant's telephone number, including area code, is (678) 620-3186.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on March 5, 2025 regarding GALECTIN THERAPEUTICS INC (GALT).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing